# **Product** Data Sheet

## (E/Z)-GSK5182

**Cat. No.:** HY-111226A **CAS No.:** 2699724-40-6

Molecular Formula:  $C_{27}H_{31}NO_3$ Molecular Weight: 417.54

Target: Estrogen Receptor/ERR; Reactive Oxygen Species

Pathway: Vitamin D Related/Nuclear Receptor; Immunology/Inflammation; Metabolic

Enzyme/Protease; NF-кВ

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months -20°C 1 month

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO:  $\geq 75 \text{ mg/mL} (179.62 \text{ mM})$ 

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.3950 mL	11.9749 mL	23.9498 mL
	5 mM	0.4790 mL	2.3950 mL	4.7900 mL
	10 mM	0.2395 mL	1.1975 mL	2.3950 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 3.75 mg/mL (8.98 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 3.75 mg/mL (8.98 mM); Suspended solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 3.75 mg/mL (8.98 mM); Clear solution

### **BIOLOGICAL ACTIVITY**

Description

(E/Z)-GSK5182 is a racemic compound of (E)-GSK5182 and (Z)-GSK5182 isomers. GSK5182 is a highly selective and orally active inverse agonist of estrogen-related receptor  $\gamma$  (ERR $\gamma$ ) with an IC $_{50}$  of 79 nM $^{[1]}$ . GSK5182 also induces reactive oxyen species (ROS) generation in hepatocellular carcinoma $^{[1]}$ [2][3].

### **REFERENCES**

- [1]. Kim JH, et al. Estrogen-related receptor  $\gamma$  is upregulated in liver cancer and its inhibition suppresses livercancer cell proliferation via induction of p21 and p27. Exp Mol Med. 2016 Mar 4;48:e213.
- [2]. Misra J, et al. ERRy: a Junior Orphan with a Senior Role in Metabolism. Trends Endocrinol Metab. 2017 Apr;28(4):261-272.
- [3]. Kim DK, et al. Inverse agonist of nuclear receptor ERRy mediates antidiabetic effect through inhibition of hepatic gluconeogenesis. Diabetes. 2013 Sep;62(9):3093-102.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA